Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Infliximab treatment strategy: dose titration based on response in patients with RA

Nature Clinical Practice Rheumatology volume 3, pages 494–495 (2007)Cite this article

boxed-textFlendrie M et al. (2007) Titration of infliximab treatment in rheumatoid arthritis patients based on response patterns. Rheumatology 46: 146–149

After an initial moderate response, adjusting dose and/or interval of infliximab infusions in patients with RA leads to improved response in a subset of patients—whether dose increase or interval shortening is superior remains to be clarified

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Grigor C et al. (2004) Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 364: 263–269

    Article  Google Scholar 

  2. Goekoop-Ruiterman YP et al. (2005) Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 52: 3381–3390

    Article  CAS  Google Scholar 

  3. Rahman MU et al. (2007) Double-blinded infliximab dose escalation in patients with rheumatoid arthritis. Ann Rheum Dis [doi:10.1136/ard.2006.065995]

  4. Hyrich KL et al. (2007) Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum 56: 13–20

    Article  CAS  Google Scholar 

  5. Wolbink GJ et al. (2005) Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis 64: 704–707

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by KP Machold.

Author information

Author notes

  1. Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Waehringer Guertel 18–20, Vienna A-1090, Austria klaus.machold@meduniwien.ac.at

Authors and Affiliations

  1. Department of Internal Medicine, KP Machold is Associate Professor of Rheumatology, at the Medical University of Vienna, Austria.,

    Klaus P Machold

Authors
  1. Klaus P Machold
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The author declares no competing financial interests.

Supplementary information

Supplementary Table 1

Dose-adjustment or interval-adjustment rules in patients classified as 'moderate responders' at week 14. In patients whose EULAR-respnses were classed as 'moderate', either dose or interval of infliximab infusions were adjusted according to the DAS28 course over the following weeks. (DOC 32 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Machold, K. Infliximab treatment strategy: dose titration based on response in patients with RA. Nat Rev Rheumatol 3, 494–495 (2007). https://doi.org/10.1038/ncprheum0575

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncprheum0575

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing